cutaneous and subcutaneous mycosis
Conditions
Interventions
tinea captitis/kerion:InterventionIntervention: the patients infected Trichophyton were treated by oral terbinafine, while those infected Microsporum treated by oral itraconazole
sporotrichosis:first, itraconazole 200-400mg/d for 3-6 months
non-dermatophytes onychomycosis:terbinafine 250mg/d for 6-16 weeks
itraconazole 200mg/d for 12 weeks or 400mg/d×7d and interval 21 days for one plus,two-three pluses for fingernail onychomycosis
three-four pluses for toenail
fluconazole 150mg/week,ten-twelve weeks for fingernail onychomycosis and 16-18 weeks for toenail
phaeohyphomycosis:itraconazole 200-400mg/d for 3-6 months
or terbinafine 250-500mg/d for 3-6 months.The severe cases were given amphotericin B for one-two months followed by itraconazole or terbinafine.
Zygomycosis:first ,amphotericin B for the severe cases from 1mg/d to 0.6-0.8mg//kg/d,for 3 months ,the total dose 25-50mg/kg followed by itraconazole 200-400mg/d for 6 months.itraconazole 200-400mg/d
or posaconazole 400-800mg/d for 3-6 months.
recurrent vulvovaginal candidiasis(RVVC):itraconazole 200mg/d or fluconazole 150mg/d for one week combined topical drug every month for 6 months
for the cases not controlled diabetes,oral zoles for 2 weeks every month for 6 months combined topical agents.
Sponsors
Institute of Dermatology, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
3 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. the cases of tinea captistis/kerion;non-dermatophytes onychomycosis; sporotrichosis; phaeohyphomycosis; Zygomycosis; RVVC, be diagnosed by mycological test and/or psthaological test; 2. Aged between 18-65 years,the cases of tinea captitis aged from 3-year; 3. take part in the research of their own accord and signed at informed consent.
Exclusion criteria
Exclusion criteria: 1. combined other dermatosis disturbed or severe bacteria infection; 2. oversensitive to the drug; 3. have severe heart,liver,kindey disease,diabetes or psychopathy; 4. system application by corticosteroid hormone or immunosuppressor in 3 months; 5. system application by antifungcal drug in 3 months or topical use of antifungal agents at 2 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the clinical response rate;the mycological clearance rate; | — |
Countries
China
Contacts
Public ContactWeida Liu
Institute of Dermatology, Chinese Academy of Medical Sciences
Outcome results
None listed